论文部分内容阅读
[目的]评价酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKI)对控制脑转移的作用。[方法]83例Ⅳ期(或复发)非小细胞肺癌(NSCLC)患者接受吉非替尼或厄洛替尼治疗,同期67例化疗患者作为对照,随访脑转移出现的时间和生存时间。[结果]经中位11.4个月的随访,TKI组脑转移发生率低于化疗组(18.29%vs 35.38%,χ2=5.5,P=0.019)。TKI组中发生脑转移的中位时间为7.6个月(6.9~8.3个月),明显长于单纯化疗组4.9个月(4.4~5.4个月)(χ2=15.6,P=0.001)。TKI组中位总生存时间为11.4个月(95%CI:10.3~12.6),长于单纯化疗组的7.5个月(95%CI:6.6~8.5)(χ2=19.3,P<0.001)。[结论]TKI降低晚期NSCLC患者脑转移的风险,延长患者的生存时间。
[Objective] To evaluate the effect of tyrosine kinase inhibitors (TKIs) on brain metastasis. [Method] Eighty-three patients with stage IV (or recurrent) non-small cell lung cancer (NSCLC) were treated with gefitinib or erlotinib. 67 patients with chemotherapy were followed up for the time and survival time of brain metastases. [Results] The median follow-up of 11.4 months showed that the incidence of brain metastases in TKI group was lower than that in chemotherapy group (18.29% vs 35.38%, χ2 = 5.5, P = 0.019). The median time to brain metastases in the TKI group was 7.6 months (6.9-8.3 months), significantly longer than 4.9 months (4.4-5.4 months) in the chemotherapy alone group (χ2 = 15.6, P = 0.001). The median overall survival in the TKI group was 11.4 months (95% CI: 10.3 to 12.6), which was longer than 7.5 months (95% CI 6.6 to 8.5) in the chemotherapy alone group (2 = 19.3, P <0.001). [Conclusion] TKI can reduce the risk of brain metastasis in patients with advanced NSCLC and prolong the survival time of patients.